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In localized breast cancer treatment is given with a curative intent.
While much attention has focused on acute treatment-related toxi-
city and its impact on patients’ quality of life during active cancer
treatment, there is less knowledge on the rehabilitation and quality
of life outcomes in women with no evidence of disease many years
after treatment. In breast cancer survivors, the evaluation of the
impact of long-term treatment side-effects on quality of life is
important in identifying difficulties, informing patients and mini-
mizing and preventing problems (Dow et al, 1996; Hietanen,
1996; Bernhard et al, 1997). Many studies have been conducted on
quality of life and psychological distress after mastectomy or
lumpectomy. Their results are all the more contradictory because
in most studies, the patient follow-up was limited (less than 2
years) (Knobf, 1986; Kiebert et al, 1991; Maunsell et al, 1993; van
Dam et al, 1998). Much less attention has been paid to the impact
of adjuvant therapy (Maguire et al, 1980; Berglund et al, 1991;
Schover et al, 1995; Hürny et al, 1996; Ganz et al, 1998a).
Nowadays, more and more patients are given adjuvant
chemotherapy (Hebert-Croteau et al, 1999). While impact of adju-
vant chemotherapy on overall survival of women with node-nega-
tive localized breast cancer is still limited, improvement of
disease-free survival has led to a consensus favouring such adju-
vant chemotherapy (Goldhirsch et al, 1995; Early Breast Cancer
Trialist’s Collaborative Group, 1998). Thus, the evaluation of
changes possibly induced by chemotherapy on the family, social
and professional life of these premenopausal women could affect
the consensus. A cross-sectional study was therefore conducted
with two objectives: first, to evaluate the impact of breast cancer
and its treatment on quality of life and rehabilitation in long-term
survivors and secondly, to explore late sequelae induced by adju-
vant chemotherapy in patients enrolled in a clinical trial.
PATIENTS AND METHODS
Selection of patients
The study was conducted among long-term survivors who were
initially enrolled in a prospective controlled clinical trial
conducted from 1980–1991 at the Polyclinique d’Oncologie
Médicale, Hôpital Saint-Louis, Paris, France. The trial compared
adjuvant CMF (cyclo-phosphamide, methotrexate, fluorouracil)
chemotherapy, given for 6-monthly courses, to no adjuvant
chemotherapy (Espié et al, 1997). Premenopausal patients with
localized node-negative breast adenocarcinoma were eligible for
the trial, in which 335 women were randomized. Patients were
eligible for the present study if they fulfilled the following criteria:
treated and followed at the Hôpital Saint-Louis, free of disease
since the end of initial therapy, and without history of second
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at Hôpital Saint-Louis, 99 had relapsed, 32 were lost to follow-up,
and one had developed a second malignancy. Therefore, 179
patients remained eligible for the study. Among these 179 patients
111 (62%) were given adjuvant CMF, a figure which parallels the
better treatment failure-free survival (TFFS) rate observed in the
chemotherapy arm compared with the rate in the no adjuvant
chemotherapy arm (10-year TFFS: 65% vs 52%, P = 0.03).
Procedure
From November 1996 to February 1997, a written invitation to
participate in the study was mailed to the 179 eligible patients, and
was followed, 2–3 weeks later, by a letter including two self-
administered questionnaires. A reminder (by mail) was sent after 1
month where necessary, and reasons for non-participation were
collected. The questionnaires were used to assess the patients’
quality of life and the difficulties they may have encountered since
their disease and its treatment. The first questionnaire was the
French language validated translation of the European
Organization for Research and Treatment of Cancer (EORTC)
QLQ-C30 core questionnaire (Aaronson et al, 1993) with the
breast module (EORTC QLQ-BR23) (Sprangers et al, 1996) after
copyright was obtained. The EORTC QLQ-C30 core question-
naire explores the following functional areas: physical, role,
emotional, cognitive and social functioning, as well as global
health status. It also includes a number of multi-item scales and
single items which assess a range of physical symptoms (fatigue,
nausea and vomiting, pain, dyspnoea, sleep disturbance, loss of
appetite, constipation, diarrhoea), as well as financial difficulties.
The breast-specific module includes four functional scales (body
image, sexual functioning, sexual enjoyment and future perspec-
tive) and a number of symptom scales and items (arm and breast
symptoms, systemic therapy side-effects, upset caused by hair-
loss). For functional scales, scores computed range from 0–100,
with the higher scores representing a higher level of functioning.
For item scales relative to symptoms and financial impact, scores
computed range from 0–100, with higher scores representing a
higher level of symptomatology or problems. The reliability of 
the core questionnaire (i.e. internal consistency measured by
Cronbach’s alpha coefficient) ranged from 0.53 for role func-
tioning to 0.94 for global health status (Osoba et al, 1994).
Although the questionnaire was designed to address patient status
during the week before interview, it also advised that some items
could be irrelevant. At the time of the study, no questionnaire was
available in French to evaluate the social and professional status of
long-term cancer survivors, as well as their medica 1 consumption.
Therefore, a second questionnaire (Life questionnaire), used previ-
ously in a survey on long-term survivors of Hodgkin’s disease
(Joly et al, 1996), was specifically compiled and tested on 20
patients prior to the study. Most items addressed in this question-
naire were objective, concerned education grade, marital status,
number of children, leisure occupations, life insurance problems,
employment and medica 1 consumption and family and social
relationships. In addition, items concerning memory of the
chemotherapy experience were added, and patients were asked to
provide their opinions on the study. All items were addressed for
the status at the time of breast cancer diagnosis and for the status in
1997. These two self-administered questionnaires were usually
completed within 45 min. Clinical data was issued from medical
charts. It concerned the date of diagnosis, the dates of beginning
and end of treatment, clinical stage, type of initial surgery
(lumpectomy, mastectomy with or without breast reconstruction),
type of radiation therapy, type of chemotherapy, and clinical
outcome including date of last visit.
Statistical analysis
Tests used for comparison of means included the Student test and
the Mann–Whitney test. Those used for proportion comparisons
were the χ 2-test and the Fisher exact test. Multivariate analysis of
variance and covariance (ANCOVA) was used for group-wise
comparisons of the quality of life-related scores with Bonferroni
correction. In the analysis, adjustments were made on comorbid
medical illnesses, age and education grade as appropriate. No
adjustment was made on treatment type (surgery, irradiation) since
it was similarly distributed among CMF and no adjuvant
chemotherapy groups. Two-sided P-values were used as descrip-
tive statistics to identify associations in the observed results.
Statistical tests were considered significant for P < 0.01. Missing
data was infrequent (< 10%) except for questions related to sexu-
ality, in particular sexual enjoyment where 25% of data was
missing. When missing, data was replaced by the mean value of
the corresponding item among respondents. Programs 4F, 3D, 7D
and 2V of the BMDP statistical software were used to analyse the
data (Dixon, 1992).
RESULTS
Participation
Among the 179 eligible patients, 122 (68%) agreed to participate, 98
spontaneously and 24 after a reminder. Of the 57 non-participants,
two refused, 19 were lost to follow-up, and 36 did not reply (Figure
1). Demographic, clinical (family history of breast cancer, tumour
size), treatment characteristics (type of surgery, proportion of
patients given CMF) and follow-up time did not statistically differ
between participants and non-participants. Of the 122 participants,
three had relapsed within a year before the questionnaires were sent,
and were excluded from the study leaving 119 patients eligible.
Patient characteristics and treatment
Clinical characteristics are listed in Table 1. All patients had
surgery with axillary clearance. Nineteen patients had breast
reconstruction 0–6 years after mastectomy (mean 1.3 years) and
15 used external breast prosthesis. Irradiation was given to 75% of
patients in the CMF group and in 67% of patients in the no adju-
vant chemotherapy group. Lumpectomy was performed in 69%
and 64% of patients in the two arms, respectively. For patients who
had mastectomy, breast reconstruction was carried out in 50% of
patients in the two arms. As per protocol, no patients received
adjuvant hormonotherapy. After the diagnosis of breast cancer and
its treatment, 48% of women (45% and 54% in the CMF and the
no adjuvant chemotherapy group, P = 0.50) had cancer-unrelated
medical history including rheumatoid disease in 30%, cardiovas-
cular disease in 12%, metabolic disorders in 12% and digestive
disease in 6%. Twenty six percent of patients in the CMF group
and 28% of those in the no adjuvant chemotherapy group had a
family history of breast cancer.
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(range 4–16). Forty six percent of patients were qualified (36%
were of management grade or higher). Most patients were married
and 84% had children, including three children born after treat-
ment was completed. At time of interview, 83% of patients were
post-menopausal. CMF patients were younger than those who
were not given adjuvant chemotherapy (53 years vs 55 years, P =
0.04). Follow-up time was shorter in the CMF group (9.1 years vs
10.5 years, P = 0.01) (Table 2).
Long-term quality of life
Seventy nine percent of patients reported a good appraisal of the
study while four (3%) patients expressed painful memories
induced by the questionnaires.
Quality of life assessed by the EORTC questionnaires
All generic quality of life scale scores were similar in patients who
were or were not given chemotherapy (Table 3). Specific dimen-
sions and symptoms of the breast module (body image and sexu-
ality) were not influenced by chemotherapy (Table 4). Education
grade correlated with score of future perspective (r = 0.2, P = 0.1)
and those of arm and breast symptoms: the higher the education
grade, the higher the functional scale score (future perspective)
and the lower the symptom scale scores (arm and breast symp-
toms). Follow-up time since initial treatment (less or more than 10
years) only influenced one quality of life scale score. In CMF
patients, the social functioning scale score was higher in patients
with follow-up of more than 10 years (97 vs 85, P = 0.006)
Life questionnaire data
At time of study, 44% of patients reported treatment-related
sequelae of any type or intensity (40% in the CMF group and 51%
in the no adjuvant chemotherapy group, P = 0.53). Chronic fatigue
was reported by 19% of CMF patients and by 31% of patients with
no adjuvant chemotherapy (P = 0.12). Overall, 56% of patients
gained weight after treatment (57% in the CMF and 55% in the no
adjuvant chemotherapy groups). Weight-gain was considered
chemotherapy-related by 2% of patients, related to chemotherapy-
induced menopause by 23% of patients, and was a consequence of
change in lifestyle in 31% of patients. Dysfunction in sexual life
was reported by 30% (16 CMF and 20 no adjuvant chemotherapy)
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179 eligible patients
  2 refusals
19 lost to follow-up
36 no reply
122 participants
3 relapses
119 patients retained for the study
CMF
(n = 77)
No adjuvant chemotherapy
(n = 42)
Figure 1 Participation in study
Table 1 Clinical characteristics (n = 119)
Variable n %
Family history of breast cancer 32 27
Clinical stage (UICC)
T0 11 8
T1–T2 103 87
T3–T4 5 5
Type of surgery
Lumpectomy 81 68
Mastectomy 19 16
Mastectomy with breast reconstruction 19 16
External beam irradiationa 86 72
Brachytherapy (boost)b 75 63
Adjuvant CMFc chemotherapy 77 65
Mean treatment duration, in days (range) 59 (36–87) –
Menopausal status at interview 99 83
a45 Gy, standard dose; b20 Gy, standard dose; ccyclo-phosphamide 
400 mg m–2, methothrexate 40 mg m–2, fluorouracil 400 mg m–2, day 1 
and day 8, q 28 days for six courses
Table 2 Demographic characteristics at interview (n = 119)
No chemotherapy CMF P value
(n = 42) n = 77)
Mean age in years (range) 55 (40–69) 53 (30–66) 0.04
Mean time from treatment in years (range) 10.5 (6–16) 9.1 (4–16) 0.01
Education grade (%)
High 21 (50) 33 (43)
Middle 18 (43) 35 (45)
Low 3 (7) 9 (12) 0.60
Annual family income, in Euroa > 18 462b (%) 26 (61) 56 (73) 0.30
Currently married (%) 35 (83) 62 (81) 0.90
Children (%) 34 (81) 66 (86) 0.70
Mean number (range) 1.5 (1–4) 1.6 (1–5) –
aData available in 109 patients; bOne Euro = 6.57957 French francsof patients. Among the 16 CMF patients, sexual dysfunction was
considered as a consequence of chemotherapy-induced menopause
in four. No difference in the proportion of patients with modifica-
tions in relationships with partner (45% vs 52%), children (21% vs
22%) or friends (24% vs 36%) was observed in the CMF group
and the no adjuvant chemotherapy group, respectively. Breast
cancer was responsible for separation or divorce in three women
only (including two CMF patients). Sentimental ties with partner
were strengthened in 29% and 39% of CMF and no adjuvant
chemotherapy patients, respectively (P = 0.5).
Professional and social difficulties issued from the life
questionnaire
At diagnosis, 78% (n = 60) of CMF patients and 64% (n = 27) of no
adjuvant chemotherapy patients were professionally active while,
at time of interview, 62% (n = 48) and 40% (n = 17) continued to
work, respectively. Among the 22 patients who stopped working,
19 had retired (11 and eight patients, respectively), and three were
unable to work while in complete remission (two and one patients,
respectively). Between breast cancer therapy and 1997, 28% (n =
25) of women at work had changed their employer or the position
occupied. Personal choice was the main reason while two women
were dismissed because of their disease (one in each group). In
four patients, the work-post was adapted because of surgery or
irradiation-related arm sequelae. Changes in professional projects
were independent of previous chemotherapy, age and education
grade. Less professional ambition was expressed by 66% and 67%
of CMF and no adjuvant chemotherapy patients, respectively,
while the disease had reinforced the professional ambitions of the
remaining patients at work. Fourteen (12%) patients (nine CMF
and five no adjuvant chemotherapy) reported financial difficulties
because of breast cancer; in six of them (three and three) the
problem was still present in 1997. Companies refused life insur-
ance to eight of 65 women requesting it. Both financial and life-
insurance difficulties were unrelated to previous chemotherapy or
time since therapy. Among the 40 patients who had borrowed
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Table 3 Chemotherapy impact on quality of life (EORTC QLQ-C30 core questionnaire): mean
values (standard deviation)a
No chemotherapy CMF P valueb
(n = 42) (n = 77)
Functional scalesc
Physical functioning 80 (20) 84 (15) 0.30
Role functioning 63 (51) 62 (62) 0.80
Emotional functioning 68 (29) 74 (24) 0.40
Cognitive functioning 83 (47) 68 (20) 0.04
Social functioning 86 (26) 89 (21) 0.66
Global health status 70 (18) 75 (18) 0.20
Symptom scales/itemsd
Fatigue 28 (24) 20 (21) 0.12
Nausea and vomiting 15 (45) 3 (10) 0.04
Pain 21 (31) 16 (21) 0.50
Dyspnoea 22 (24) 16 (23) 0.20
Sleep disturbance 38 (39) 24 (31) 0.05
Appetite loss 12 (24) 4 (16) 0.09
Constipation 19 (32) 15 (28) 0.68
Diarrhoea 4 (12) 4 (11) 0.90
Financial difficulties 5 (23) 7 (19) 0.55
aWith minor variations in sample size because of missing data; bCovariance analysis (ANCOVA)
with correction for co-morbid medical illness, menopausal status at interview and time since
treatment; cA high scale score represents a high level of functioning; dA high scale score
represents a high level of symptomatology or problem
Table 4 Chemotherapy impact on quality of life (EORTC breast module): mean values
(standard deviation)a
No chemotherapy CMF P valueb
(n = 42) (n = 77)
Functional scalesc
Future perspective 57 (34) 55 (36) 0.60
Body image 80 (26) 76 (29) 0.70
Sexual functioning 26 (28) 35 (26) 0.40
Sexual enjoyment 47 (21) 60 (32) 0.10
Symptom scales/itemsd
Breast symptoms 18 (21) 20 (21) 0.60
Arm symptoms 19 (20) 18 (20) 0.80
aWith minor variations in sample size because of missing data; bCovariance analysis
(ANCOVA) with correction for age and co-morbid medical illness, menopausal status at
interview and time since treatment; cA high scale score represents a high level of functioning;
dA high scale score represents a high level of symptomatology or problemmoney from banks, 20 (50%) reported difficulties in subscription
(higher interest rate, restriction of the contract, refusal) indepen-
dently of previous chemotherapy.
DISCUSSION
Many studies have explored quality of life and difficulties experi-
enced by women with breast cancer both during treatment and in
the short post-treatment period (Halttunen et al, 1992; Dorval et al,
1998; Ganz et al, 1998a). In contrast, no studies have explored
long-term consequences of chemotherapy for breast cancer. A
study, therefore, was conducted in long-term breast cancer
survivors of localized disease, who were enrolled in a clinical trial
comparing adjuvant CMF to no adjuvant chemotherapy (Espié et
al, 1997). The study focused on node-negative young women with
an average follow-up of 10 years. In contrast to published studies
in which all non-metastatic breast cancer patients were considered,
the study concerns a subgroup of patients for whom the treatment
strategy today includes adjuvant chemotherapy (Goldhirsch et al,
1995; Early Breast Cancer Trialist’s Collaborative Group, 1998).
The results indicate that women have coped with the disease,
achieving a satisfactory global quality of life irrespective of the
adjuvant treatment administered. Although women report
persisting symptoms related to their cancer and its treatment, many
positive benefits are gained which help to balance the negative
aspects (Dow et al, 1996; Ganz et al, 1998b).
Adjuvant chemotherapy has been reported to partially influence
quality of life during or after the treatment period (McArdle, 1979;
Maguire et al, 1980; Palmer et al, 1980; Hughson et al, 1986;
Knobf, 1986; Schover et al, 1995). Its effect is transient and minor
compared with patients’ adjustment or coping after diagnosis and
surgery (Hürny et al, 1996). The limited impact of chemotherapy
can relate to the mild physical distress that persists after the treat-
ment, with minimal alteration in life style and little change in
sexual relationships (Knobf, 1986). Two–5 years after adjuvant
therapy self-rated quality of life in breast cancer patients is gener-
ally good, although selected aspects (sexual acceptance by the
partner, negative feelings toward sexual relations) appear to be
compromised in less than half of the women (Ganz et al, 1998a).
In the present study, patients who received adjuvant chemotherapy
do not report more sexual and body-image dysfunction than those
who had not, a result that can be explained by a longer follow-up,
with improved coping with time. Another difference concerns
tools used to evaluate the sexuality that are very limited in French
and probably not very relevant. However, cultural differences in
the USA and in Europe cannot be neglected. While body-image
problems and sexual disorders are frequently reported (Schover et
al, 1995; Dow et al, 1996; Ganz et al, 1996; Barni and Mondin,
1997), the influence of chemotherapy upon sexual satisfaction is
not clear (Ganz et al, 1998b). Although some physical symptoms
(such as prematurely chemotherapy-induced menopause) have the
potential to detract from sexual activity, other independent phys-
ical and psychological factors may in fact predominate as determi-
nants of sexual functioning, such as age-related changes in desire,
arousal and quality of partnered relationships (Ganz et al, 1999).
Nowadays, anthracycline-containing regimens are more
commonly used in node-positive premenopausal breast cancer
patients, inducing more acute toxicity, such as alopecia and
nausea, than CMF. One cannot exclude, in the future, a significant
impact of adjuvant chemotherapy on long-term psychological
disorders, since more cognitive impairment in patients with
anthracycline-containing chemotherapy have been reported (van
Dam et al, 1998). Moreover, the difference is higher in patients
receiving high-dose chemotherapy than in patients receiving stan-
dard-dose, and higher in the latter than in patients without adjuvant
chemotherapy.
Arm and breast symptoms may persist many years after the end
of treatment. Main complaints concerning pain, weakness, stiff-
ness and some limitation in range of movement are surgery and/or
irradiation-related, and not chemotherapy-related (Kiebert et al,
1991; Maunsell et al, 1993). Even if these symptoms are reported
often, they seem to only moderately influence the long-term
patient quality of life (Craig et al, 1974; Ganz et al, 1996; Dorval et
al, 1998; Lindley et al, 1998).
Even 10 years after diagnosis and treatment, other mild social
problems or difficulties are still reported. A major difficulty
encountered by survivors concerns life insurance (which is manda-
tory for borrowing money from banks), while difficulties in
patient’s work are rarely reported (Dow et al, 1996; Ganz et al,
1996). However, the problem appears to be less important in
female breast cancer survivors than in men surviving cancer,
because a majority of women are married and their spouse can on
some occasions request insurance in their own name (Joly et al,
1996). Past adjuvant chemotherapy does not appear to influence
problems and refusal from banks and insurance companies, which
are more likely to be related to personal history of cancer than to
its treatment.
Our study highlights that with long follow-up, most
premenopausal node-negative women treated for localized breast
cancer cope with the disease and its treatment. In particular, adju-
vant CMF chemotherapy does not appear to impair quality of life
nor social and professional life in these patients.
ACKNOWLEDGEMENTS
This study was supported by a grant from the Fondation de France.
REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A,
Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi
D, Rofe PB, Schraub S, Sneeuw K, Sullivan M and Takeda F (1993) The
EORTC QLQ-C30: A quality of life instrument for use in international clinical
trials in oncology. J Natl Cancer Inst 85: 365–376
Barni S and Mondin R (1997) Sexual dysfunction in treated breast cancer patients.
Ann Oncol 8: 149–153
Berglund G, Bolund C, Fornander T, Rutqvist LE and Sjoden PO (1991) Late effects
of adjuvant chemotherapy and postoperative radiotherapy on quality of life
among breast cancer patients. Eur J Cancer 27: 1075–1081
Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD,
Goldhirsch A, Senn HJ and Rudenstam CM (1997) Quality of life assessment
in patients receiving adjuvant therapy for breast cancer: The IBCSG approach.
Ann Oncol 8: 825–835
Craig TJ, Comstock GW and Geiser PB (1974) The quality of survival in breast
cancer: A case-control comparison. Cancer 33: 1451–1457
Dixon WJ (1992) BMDP statistical software Release 7.0. University of California
Press: Berkeley
Dorval M, Maunsell E, Deschênes L, Brisson J and Mâsse B (1998) Long-term
quality of life after breast cancer: Comparison of 8-year survivors with
population controls. J Clin Oncol 16: 487–494
Dow KH, Ferrell BR, Leigh S, Ly J and Gulasekaram P (1996) An evaluation of the
quality of life among long-term survivors of breast cancer. Breast Cancer Res
Treat 39: 261–273
Early Breast Cancer Trialist’s Collaborative Group (EBCTCG) (1998)
Polychemotherapy for early breast cancer: An overview of the randomised
trials. Lancet 352: 930–942
Long-term quality of life and localized breast cancer 581
British Journal of Cancer (2000) 83(5), 577–582 © 2000 Cancer Research CampaignEspié M, Mignot L, Leleu F, De Roquancourt A, Maylin C, Morvan F, Clot P and
Marty M (1997) Improved outcome of node negative breast cancer in
premenopausal women with adjuvant CMF: Results of a randomized study.
Proc ASCO 16: 141 (Abstr)
Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML and Petersen L (1996) Breast
cancer survivors: Psychosocial concerns and quality of life. Breast Cancer Res
Treat 38: 183–199
Ganz PA, Rowland JH, Meyerowitz BE and Desmond K (1998a) Impact of different
adjuvant therapy strategies on quality of life in breast cancer survivors. Recent
Results Cancer Res 152: 396–411
Ganz PA, Rowland JH, Desmond K, Meyerowitz BE and Wyatt GE (1998b) Life
after breast cancer: Understanding women’s health-related quality of life and
sexual functioning. J Clin Oncol 16: 501–514
Ganz PA, Desmond KA, Belin TR, Meyerowitz BE and Rowland JH (1999)
Predictors of sexual health in women after a breast cancer diagnosis. J Clin
Oncol 17: 2371–2380
Goldhirsch A, Wood WC, Senn HJ, Glick JH and Gelber RD (1995) Fifth
international conference on adjuvant therapy of breast cancer, St Gallen, March
1995. International consensus panel on the treatment of primary breast cancer.
Eur J Cancer 31A: 1754–1759
Halttunen A, Hietanen P, Jallinoja P and Lonnqvist J (1992) Getting free of breast
cancer. An eight-year perspective of the relapse-free patients. Acta Oncol 31:
307–310
Hebert-Croteau N, Brisson J, Latreille J, Gariepy G, Blanchette C and Deschênes L
(1999) Time trends in systemic adjuvant treatment for node negative breast
cancer. J Clin Oncol 17: 1458–1464
Hietanen PS (1996) Measurement and practical aspects of quality of life in breast
cancer. Acta Oncol 35: 39–42
Hughson AV, Cooper AF, McArdle CS and Smith DC (1986) Psychological impact
of adjuvant chemotherapy in the first two years after mastectomy. BMJ 293:
1268–1271
Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peteron HF, Gelber RD,
Forbes JF, Rudenstam CM, Simoncini E, Crivellai D, Goldhirsch A and Senn
HJ (1996) Impact of adjuvant therapy on quality of life in women with node-
positive operable breast cancer. Lancet 347: 1279–1284
Joly F, Henry-Amar M, Arveux P, Reman O, Tanguy A, Pény AM, Lebailly P, Macé-
Lesec’h J, Vié B, Génot JY, Busson A, Troussard X and Leporrier M (1996)
Late psychosocial sequelae in Hodgkin’s disease survivors: A French
population-based case-control study. J Clin Oncol 14: 2444–2453
Kiebert GM, de Haes JCJM and van de Velde CJH (1991) The impact of breast-
conserving treatment and mastectomy on the quality of life of early-stage
breast cancer patients: A review. J Clin Oncol 9: 1059–1070
Knobf MT (1986) Physical and psychologic distress associated with adjuvant
chemotherapy in women with breast cancer. J Clin Oncol 4: 678–684
Lindley C, Vasa S, Sawyer WT and Winer EP (1998) Quality of life and preferences
for treatment following systemic adjuvant therapy for early-stage breast cancer.
J Clin Oncol 16: 1380–1387
Maguire GP, Tait A, Brooke M, Thomas C, Howat JM, Sellwood RA and Bush H
(1980) Psychiatric morbidity and physical toxicity associated with adjuvant
chemotherapy after mastectomy. BMJ 281: 1179–1180
Maunsell E, Brisson J and Deschenes L (1993) Arm problems and psychological
distress after surgery for breast cancer. Can J Surg 36: 315–320
McArdle CS (1979) The emotional and social implication of adjuvant chemotherapy
in breast cancer. In Adjuvant therapy of cancer, Salmon SE (ed) pp 319–325.
Crune and Stratton: Orlando
Osoba D, Zee B, Warr D, Kaizer L and Latreille J (1994) Psychometric
properties and responsiveness of the EORTC quality of life questionnaire
(QLQ-C30) in patients with breast ovarian and lung cancer. Qual Life Res
3: 353–364
Palmer BV, Walsh GA, McKinna JA and Greening WP (1980) Adjuvant
chemotherapy for breast cancer: Side effects and quality of life. BMJ 281:
1594–1597
Schover LR, Yetman RJ, Tuason LJ, Meisler E, Esselstyn CB, Hermann RE,
Grundfest-Broniatowski S and Dowden RV (1995) Partial mastectomy and
breast reconstruction. A comparison of their effects on psychosocial
adjustment, body image, and sexuality. Cancer 75: 54–64
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini
L, Williams A, de Haes HC, Hopwood P, Cull A and Aaronson NK (1996) The
European Organization for Research and Treatment of Cancer breast cancer-
specific quality-of-life questionnaire module: First results from a three-country
field study. J Clin Oncol 14: 2756–2768
van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall VD, Droogleever FME and
Rodenhuis S (1998) Impairment of cognitive function in women receiving
adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose
chemotherapy. J Natl Cancer Inst 90: 210–218
582 F Joly et al
British Journal of Cancer (2000) 83(5), 577–582 © 2000 Cancer Research Campaign